- Home
- TRAW
TRAW
TRAWS PHARMA INC
as 11-14-2024 9:48am EST
Stocks
Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.
Upcoming Earnings Alert:
Get ready for potential market movements as TRAWS PHARMA INC TRAW prepares to release earnings report on 20 Nov 2024.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | NEWTOWN |
| Market Cap: | 15.0M | IPO Year: | 2013 |
| Target Price: | N/A | AVG Volume (30 days): | 9.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -155.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.44 - $27.50 | Next Earning Date: | 11-20-2024 |
| Revenue: | $226,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 2.9% | Revenue Growth (next year): | -49.56% |
Latest TRAWS PHARMA INC News
TRAW Breaking Stock News: Dive into TRAW Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
GlobeNewswire
2 months ago
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
GuruFocus.com
2 months ago
Orbimed Advisors LLC Reduces Stake in Traws Pharma Inc
TipRanks
2 months ago
Upcoming Stock Splits This Week (September 23 to September 27) – Stay Invested
GlobeNewswire
2 months ago
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
GlobeNewswire
2 months ago
Traws Pharma, Inc. Announces Special Shareholders Meeting Results
GlobeNewswire
3 months ago
Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
GlobeNewswire
3 months ago
Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET
Compare TRAW vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TRAW TRAWS PHARMA INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.